Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The influence of Hashimoto's thyroiditis (HT) with subclinical hypothyroidism or euthyroid status on the alteration of glucagon-like peptide (GLP)-1 and GLP-2 levels remains uncertain.
Materials And Methods: Twenty-four untreated HT patients with subclinical hypothyroidism, 24 euthyroid HT patients, and 24 age- and gender-matched controls were enrolled in the study. The levels of GLP-1, GLP-2, glucose, glycated albumin, insulin, thyroid hormone, and thyroid autoantibodies were measured and evaluated.
Results: The levels of GLP-1, blood glucose, and triglyceride were higher in HT patients with subclinical hypothyroidism than in controls (all P < 0.05, respectively). However, the above variables, including GLP-2, were similar in euthyroid patients and controls. Neither GLP-1 nor GLP-2 was correlated with thyroid hormone, thyroid autoantibodies or metabolic parameters.
Conclusion: The serum levels of GLP-1, not GLP-2, were increased in patients with subclinical hypothyroidism. Our data suggest that subclinical hypothyroidism affects circulating GLP-1 levels.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400714 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Gut Hormone Levels During Mixed Liquid Meal Test in Short Bowel Syndrome, the Possible Influence on the Intestine Adaptation.
Physiol Res
August 2025
3rd Department of Internal Medicine, Department of endocrinology and metabolism, General University Hospital in Prague, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
Short bowel syndrome (SBS) is an intestinal disorder characterized by reduced length of the gut most due to intestinal resection, resulting in malabsorption, malnutrition, and water and electrolyte disturbances. Intestinal adaptation is a long-term process in which GIT hormones, growth peptides, cytokines etc. are involved.
View Article and Find Full Text PDFThe separate and combined effects of GIP, GLP-1 and GLP-2 on markers of bone turnover in type 2 diabetes.
J Clin Endocrinol Metab
August 2025
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Context: Oral glucose tolerance test (OGTT) induces greater acute suppression of bone resorption than isoglycaemic intravenous glucose infusions (IIGI).
Objective: To study the separate and combined effects of the gut-derived hormones glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1) and glucagon-like peptide 2 (GLP-2) on postprandial bone turnover.
Design: A randomized, crossover study with 6 experimental days.
Long-term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli-durability 24-month observational study.
Diabetes Obes Metab
October 2025
Diabetes Research Centre, University of Leicester, Leicester, UK.
Aim: To evaluate the effectiveness and safety of a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi) over 24 months in people with type 2 diabetes (T2D).
Methods: In this retrospective, observational study, data were collected from the Optum Market Clarity® database in the United States. People with T2D aged ≥18 years, previously treated with oral antidiabetic drugs ± basal insulin or glucagon-like peptide-1 receptor agonists, who initiated iGlarLixi between 1 January 2017 and 31 March 2020 and received ≥1 iGlarLixi prescription were included.
Gut Hormones and Inflammatory Bowel Disease.
Biomolecules
July 2025
Department of Biomedical Sciences and Diabetes Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, USA.
Obesity-driven inflammation disrupts gut barrier integrity and promotes inflammatory bowel disease (IBD). Emerging evidence highlights gut hormones-including glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), glucose-dependent insulinotropic polypeptide (GIP), peptide YY (PYY), cholecystokinin (CCK), and apolipoprotein A4 (APOA4)-as key regulators of metabolism and mucosal immunity. This review outlines known mechanisms and explores therapeutic prospects in IBD.
View Article and Find Full Text PDFProglucagon-derived Peptides: Human Physiology and Therapeutic Potential.
Physiol Rev
July 2025
Center for Clinical Metabolic Research, Herlev and Gentofte University Hospital, Copenhagen, Denmark.
Proglucagon-derived peptides represent a class of peptide hormones derived from the proglucagon precursor. These peptides, including glucagon, glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2) and oxyntomodulin, exert diverse effects on several aspects of human physiology, ranging from glucose, lipid and protein metabolism to appetite regulation, nutrient absorption and gastrointestinal motility. Their actions are mediated by distinct G protein-coupled receptors, influencing endocrine, neuroendocrine, and metabolic processes, and over recent decades, the proglucagon-derived peptides have emerged as central players in the management of metabolic and gastrointestinal diseases.
View Article and Find Full Text PDF